How to help the aging male? Current approaches to hypogonadism in primary care

References

• Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM; Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–2559.
   PubMed Web of Science ®Google Scholar
• Wang C, Nieschlag E, Swerdloff RS, Behre H, Hellstrom WJ, Gooren LJ, Kaufman JM, et al. ISA, ISSAM, EAU, EAA and ASA recommendations: investigation, treatment and monitoring of late-onset hypogonadism in males. Aging Male 2009;12:5–12.
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Faber S, Nieschlag E. Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 2006;91:4335–4343.
   PubMed Web of Science ®Google Scholar
• Behre HM, Tammela TL, Arver S, Tolrá JR, Bonifacio V, Lamche M, Kelly J, et al.; for the European Testogel® Study Team®. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. Aging Male 2012 Jul 26. [Epub ahead of print].
   Google Scholar
• Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004;172:658–663.
   PubMed Web of Science ®Google Scholar
• Wu FC, Tajar A, Beynon JM, Pye SR, Silman AJ, Finn JD, O’Neill TW, et al.; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010;363:123–135.
   PubMed Web of Science ®Google Scholar
• Araujo AB, O’Donnell AB, Brambilla DJ, Simpson WB, Longcope C, Matsumoto AM, McKinlay JB. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89:5920–5926.
   PubMed Web of Science ®Google Scholar
• Araujo AB, Esche GR, Kupelian V, O’Donnell AB, Travison TG, Williams RE, Clark RV, McKinlay JB. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007;92:4241–4247.
   PubMed Web of Science ®Google Scholar
• Tamler R, Deveney T. Hypogonadism, erectile dysfunction, and type 2 diabetes mellitus: what the clinician needs to know. Postgrad Med 2010;122:165–175.
   PubMed Web of Science ®Google Scholar
• Barkin J. Erectile dysfunction and low testosterone: cause or an effect? Can J Urol 2010;17 Suppl 1:2–11.
   Google Scholar
• Arver S, Dobs AS, Meikle AW, Allen RP, Sanders SW, Mazer NA. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 1996;155:1604–1608.
   PubMed Web of Science ®Google Scholar
• Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911–917.
   PubMed Web of Science ®Google Scholar
• Biswas M, Hampton D, Newcombe RG, Rees DA. Total and free testosterone concentrations are strongly influenced by age and central obesity in men with type 1 and type 2 diabetes but correlate weakly with symptoms of androgen deficiency and diabetes-related quality of life. Clin Endocrinol (Oxf) 2012;76:665–673.
   PubMed Web of Science ®Google Scholar
• Dandona P, Rosenberg MT. A practical guide to male hypogonadism in the primary care setting. Int J Clin Pract 2010;64:682–696.
   PubMed Web of Science ®Google Scholar
• Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006;60:762–769.
   PubMed Web of Science ®Google Scholar
• Wu FC, Tajar A, Pye SR, Silman AJ, Finn JD, O’Neill TW, Bartfai G, et al.; European Male Aging Study Group. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008;93:2737–2745.
   PubMed Web of Science ®Google Scholar
• Huhtaniemi I, Forti G. Male late-onset hypogonadism: pathogenesis, diagnosis and treatment. Nat Rev Urol 2011;8:335–344.
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, Salonen JT. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 2005;90:712–719.
   PubMed Web of Science ®Google Scholar
• Traish AM, Guay A, Feeley R, Saad F. The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction. J Androl 2009;30:10–22.
   PubMed Web of Science ®Google Scholar
• Miner MM, Khera M, Bhattacharya RK, Blick G, Kushner H. Baseline data from the TRiUS registry: symptoms and comorbidities of testosterone deficiency. Postgrad Med 2011;123:17–27.
   PubMed Web of Science ®Google Scholar
• Mellström D, Johnell O, Ljunggren O, Eriksson AL, Lorentzon M, Mallmin H, Holmberg A, et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res 2006;21:529–535.
   PubMed Web of Science ®Google Scholar
• Travison TG, Araujo AB, Beck TJ, Williams RE, Clark RV, Leder BZ, McKinlay JB. Relation between serum testosterone, serum estradiol, sex hormone-binding globulin, and geometrical measures of adult male proximal femur strength. J Clin Endocrinol Metab 2009;94:853–860.
   PubMed Web of Science ®Google Scholar
• Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med 2008;358:1474–1482.
   PubMed Web of Science ®Google Scholar
• Rietschel P, Corcoran C, Stanley T, Basgoz N, Klibanski A, Grinspoon S. Prevalence of hypogonadism among men with weight loss related to human immunodeficiency virus infection who were receiving highly active antiretroviral therapy. Clin Infect Dis 2000;31:1240–1244.
   PubMed Web of Science ®Google Scholar
• Dobs AS, Few WL 3rd, Blackman MR, Harman SM, Hoover DR, Graham NM. Serum hormones in men with human immunodeficiency virus-associated wasting. J Clin Endocrinol Metab 1996;81:4108–4112.
   PubMed Web of Science ®Google Scholar
• Arver S, Sinha-Hikim I, Beall G, Guerrero M, Shen R, Bhasin S. Serum dihydrotestosterone and testosterone concentrations in human immunodeficiency virus-infected men with and without weight loss. J Androl 1999;20:611–618.
   PubMed Web of Science ®Google Scholar
• Zarrouf FA, Artz S, Griffith J, Sirbu C, Kommor M. Testosterone and depression: systematic review and meta-analysis. J Psychiatr Pract 2009;15:289–305.
   PubMed Web of Science ®Google Scholar
• Ohlsson C, Barrett-Connor E, Bhasin S, Orwoll E, Labrie F, Karlsson MK, Ljunggren O, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol 2011;58:1674–1681.
   PubMed Web of Science ®Google Scholar
• Gray A, Feldman HA, McKinlay JB, Longcope C. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991;73:1016–1025.
   PubMed Web of Science ®Google Scholar
• Orwoll E, Lambert LC, Marshall LM, Phipps K, Blank J, Barrett-Connor E, Cauley J, et al. Testosterone and estradiol among older men. J Clin Endocrinol Metab 2006;91:1336–1344.
   PubMed Web of Science ®Google Scholar
• Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR, Baltimore Longitudinal Study of Aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab 2001;86(2):724–731.
   PubMedGoogle Scholar
• Bassil N. Late-onset hypogonadism. Med Clin North Am 2011;95:507–23.
   PubMed Web of Science ®Google Scholar
• Lunenfeld B, Nieschlag E. Testosterone therapy in the aging male. Aging Male 2007;10:139–153.
   PubMed Web of Science ®Google Scholar
• Couillard C, Gagnon J, Bergeron J, Leon AS, Rao DC, Skinner JS, Wilmore JH, et al. Contribution of body fatness and adipose tissue distribution to the age variation in plasma steroid hormone concentrations in men: the HERITAGE Family Study. J Clin Endocrinol Metab 2000;85:1026–1031.
   PubMed Web of Science ®Google Scholar
• Mårin P, Arver S. Androgens and abdominal obesity. Baillieres Clin Endocrinol Metab 1998;12:441–451.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Pencina M, Jasuja GK, Travison TG, Coviello A, Orwoll E, Wang PY, et al. Reference ranges for testosterone in men generated using liquid chromatography tandem mass spectrometry in a community-based sample of healthy nonobese young men in the Framingham Heart Study and applied to three geographically distinct cohorts. J Clin Endocrinol Metab 2011;96:2430–2439.
   PubMed Web of Science ®Google Scholar
• Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, Lenzi A, et al. Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med 2011;8:272–283.
   PubMed Web of Science ®Google Scholar
• Gooren L. Frailty and its relationship to late onset hypogonadism. J Men’s Health & Gender 2007;4:466–473.
   Google Scholar
• Janssen I. Influence of sarcopenia on the development of physical disability: the Cardiovascular Health Study. J Am Geriatr Soc 2006;54:56–62.
   PubMed Web of Science ®Google Scholar
• Seftel A. Male hypogonadism. Part II: etiology, pathophysiology, and diagnosis. Int J Impot Res 2006;18:223–228.
   PubMed Web of Science ®Google Scholar
• Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007;116:2694–2701.
   PubMed Web of Science ®Google Scholar
• Carrero JJ, Qureshi AR, Parini P, Arver S, Lindholm B, Bárány P, Heimbürger O, Stenvinkel P. Low serum testosterone increases mortality risk among male dialysis patients. J Am Soc Nephrol 2009;20:613–620.
   Google Scholar
• Morley JE, Perry HM 3rd, Kevorkian RT, Patrick P. Comparison of screening questionnaires for the diagnosis of hypogonadism. Maturitas 2006;53:424–429.
   PubMed Web of Science ®Google Scholar
• Arver S, Lehtihet M. Current guidelines for the diagnosis of testosterone deficiency. In: Jones TH. editor. Advances in the Management of Testosterone Deficiency. Front Horm Res, Basel: Karger; 2009, vol 37. pp 5–20.
   Google Scholar
• AACE Hypogonadism Task Force. American Association Of Clinical Endocrinologists Medical Guidelines For Clinical Practice For The evaluation and treatment of hypogonadism in adult male patients 2002. Endocr Pract 2002;8:439–456.
   Google Scholar
• Cunningham AM, Matsumoto RS, Swerdloff R. Patient’s Guide to Low Testosterone 2003. The Hormone Foundation. Available from URL: http://www.hormone.org/Resources/Patient_Guides/upload/patients_guide_low_testosterone.pdf (Accessed 25 October 2011).
   Google Scholar
• Brunton SA, Sadovsky R. Late-onset male hypogonadism and testosterone replacement therapy in primary care. J Fam Pract 2010;59:S1–S8.
   Web of Science ®Google Scholar
• Dohle GR, Arver S, Bettocchi C, Kliesch S, Punab M, de Ronde W. Guidelines on male hypogonadism. European Association of Urology 2012. Available from: http://www.uroweb.org/gls/pdf/16_Male_Hypogonadism_LR%20II.pdf (Accessed April 2012).
   Google Scholar
• Shames D, Gassman A, Handelsman H. Commentary: Guideline for male testosterone therapy: a regulatory perspective. J Clin Endocrinol Metab 2007;92:414–415.
   PubMed Web of Science ®Google Scholar
• Miner M, Canty DJ, Shabsigh R. Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices. Postgrad Med 2008;120:130–153.
   PubMed Web of Science ®Google Scholar
• Yassin A, Saad F, Diede HE. Combination therapy for erectile dysfunction with testosterone and tadalafil in hypogonadal patients who failed to respond to tadalafil alone. AJU 2003;1:10–12.
   Google Scholar
• Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94–99.
   PubMedGoogle Scholar
• Amano T, Imao T, Takemae K, Iwamoto T, Nakanome M. Testosterone replacement therapy by testosterone ointment relieves lower urinary tract symptoms in late onset hypogonadism patients. Aging Male 2010;13:242–246.
   PubMed Web of Science ®Google Scholar
• Karazindiyanoglu S, Cayan S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male 2008;11:146–149.
   PubMed Web of Science ®Google Scholar
• Yassin AA, El-Sakka AI, Saad F, Gooren LJ. Lower urinary-tract symptoms and testosterone in elderly men. World J Urol 2008;26:359–364.
   PubMed Web of Science ®Google Scholar
• Frederiksen L, Højlund K, Hougaard DM, Brixen K, Andersen M. Testosterone therapy increased muscle mass and lipid oxidation in aging men. Age (Dordr) 2012;34:145–156.
   PubMed Web of Science ®Google Scholar
• Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, Morales AM, et al.; TIMES2 Investigators. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011;34:828–837.
   PubMed Web of Science ®Google Scholar
• Shores MM, Smith NL, Forsberg CW, Anawalt BD, Matsumoto AM. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab 2012;97:2050–2058.
   PubMed Web of Science ®Google Scholar
• Carson CC 3rd, Rosano G. Exogenous testosterone, cardiovascular events, and cardiovascular risk factors in elderly men: a review of trial data. J Sex Med 2012;9:54–67.
   Web of Science ®Google Scholar
• Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol 2004;172:920–922.
   PubMed Web of Science ®Google Scholar
• Park NC, Yan BQ, Chung JM, Lee KM. Oral testosterone undecanoate (Andriol) supplement therapy improves the quality of life for men with testosterone deficiency. Aging Male 2003;6:86–93.
   PubMedGoogle Scholar
• Bagchus WM. Bioequivalence of Andriol and Andriol Testocaps. Aging Male 2001;4:259.
   Google Scholar
• Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS. Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy 2003;23:319–325.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Haffejee M. Testosterone depot injection in male hypogonadism: a critical appraisal. Clin Interv Aging 2007;2:577–590.
   PubMed Web of Science ®Google Scholar
• Giagulli VA, Triggiani V, Corona G, Carbone D, Licchelli B, Tafaro E, Resta F, et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: focus on new formulations. Curr Pharm Des 2011;17:1500–1511.
   PubMed Web of Science ®Google Scholar
• Lakshman KM, Kaplan B, Travison TG, Basaria S, Knapp PE, Singh AB, LaValley MP, et al. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab 2010;95:3955–3964.
   Google Scholar
• Edelstein D, Basaria S. Testosterone undecanoate in the treatment of male hypogonadism. Expert Opin Pharmacother 2010;11:2095–2106.
   PubMed Web of Science ®Google Scholar
• Minnemann T, Schubert M, Freude S, Hübler D, Gouni-Berthold I, Schumann C, Christoph A, et al. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. J Endocrinol Invest 2008;31:718–723.
   PubMed Web of Science ®Google Scholar
• Haider A, Gooren LJ, Padungtod P, Saad F. A safety study of administration of parenteral testosterone undecanoate to elderly men over minimally 24 months. Andrologia 2010;42:349–355.
   Web of Science ®Google Scholar
• Reuters 2009. http://www.reuters.com/article/2009/12/03/idUS128821+03-Dec-2009+PRN20091203.
   Google Scholar
• Miner MM, Sadovsky R. Evolving issues in male hypogonadism: evaluation, management, and related comorbidities. Cleve Clin J Med 2007;74 Suppl 3:S38–S46.
   PubMedGoogle Scholar
• Loizides E, Swierzewski MJ, O’Neill C, Griesser J, Smith T. Early Response Time in Sexual Activity and Mood Following Testosterone Gel Replacement in Hypogonadal Males from the Testim® START Study. Rev Urol 2004;6 Suppl 6:S16–S21.
   Google Scholar
• Dean JD, Carnegie C, Rodzvilla J, Smith T. Long-term effects of testim® 1% testosterone gel in hypogonadal men. Rev Urol 2004;6 Suppl 6:S22–S29.
   Google Scholar
• McNicholas T, Ong T. Review of Testim gel. Expert Opin Pharmacother 2006;7:477–484.
   PubMed Web of Science ®Google Scholar
• Steidle S, Schwartz K, Jacoby T, Sebree T, Smith T, Bachand R. North American AA2500 T Gel Study Group. AA2500 Testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88(6):2673–2681.
   Google Scholar
• McNicholas TA, Dean JD, Mulder H, Carnegie C, Jones NA. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003;91:69–74.
   PubMed Web of Science ®Google Scholar
• Khera M, Bhattacharya RK, Blick G, Kushner H, Nguyen D, Miner MM. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS). J Sex Med 2011;8:3204–3213.
   PubMedGoogle Scholar
• Bhattacharya RK, Khera M, Blick G, Kushner H, Nguyen D, Miner MM. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS). BMC Endocr Disord 2011;11:18.
   PubMed Web of Science ®Google Scholar
• Marbury E, Hamill R, Bachand T, Sebree T, Smith T. Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel. Biopharm Drug Dispos 2003;24:115–120.
   PubMed Web of Science ®Google Scholar
• Grober ED, Khera M, Soni SD, Espinoza MG, Lipshultz LI. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men. Int J Impot Res 2008;20:213–217.
   PubMedGoogle Scholar
• Steidle C, Witt MA, Matrisciano J, Block JE. Sexual functioning and satisfaction in nonresponders to testosterone gel: Potential effectiveness of retreatment in hypogonadal males. Clin Cornerstone 2005;7 Suppl 4:S20–S25.
   Google Scholar
• Schrader S, Mills A, Scheperle M, Block JE. Improvement in sexual functioning and satisfaction in nonresponders to testosterone gel: clinical effectiveness in hypogonadal, HIV-positive males. Clin Cornerstone 2005;7 Suppl 4:S26–S31.
   Google Scholar